drugset / Trial / NCT00785915

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

NCT00785915

Phase 1 Completed 40 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD6765 in healthy male and female Japanese and Caucasian subjects

Timeline

Start
2008-11
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject lanicemine Small molecule

Indications

No indication recorded.